Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide

被引:248
作者
Boger, DL
Sato, H
Lerner, AE
Hedrick, MP
Fecik, RA
Miyauchi, H
Wilkie, GD
Austin, BJ
Patricelli, MP
Cravatt, BF
机构
[1] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
关键词
D O I
10.1073/pnas.97.10.5044
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 [理学]; 0710 [生物学]; 09 [农学];
摘要
The development of exceptionally potent inhibitors of fatty acid amide hydrolase (FAAH), the enzyme responsible for the degradation of oleamide (an endogenous sleep-inducing lipid), and anandamide (an endogenous ligand for cannabinoid receptors) is detailed. The inhibitors may serve as useful tools to clarify the role of endogenous oleamide and anandamide and may prove to be useful therapeutic agents for the treatment of sleep disorders or pain. The combination of several features-an optimal C12-C8 chain length, pi-unsaturation introduction at the corresponding arachidonoyl Delta(8,9)/Delta(11,12) and oleoyl Delta(9,10) location, and an alpha-keto N4 oxazolopyridine with incorporation of a second weakly basic: nitrogen provided FAAH inhibitors with K(i)s that drop below 200 pM and are 10(2)-10(3) times more potent than the corresponding trifluoromethyl ketones.
引用
收藏
页码:5044 / 5049
页数:6
相关论文
共 74 条
[1]
Peptidyl alpha-keto thiazole as potent thrombin inhibitors [J].
Akiyama, Y ;
Tsutsumi, S ;
Hatsushiba, E ;
Ohuchi, S ;
Okonogi, T .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (05) :533-538
[2]
IDENTIFICATION OF FATTY-ACID AMIDES IN HUMAN-PLASMA [J].
ARAFAT, ES ;
TRIMBLE, JW ;
ANDERSEN, RN ;
DASS, C ;
DESIDERIO, DM .
LIFE SCIENCES, 1989, 45 (18) :1679-1687
[3]
Cannabinoid receptors and their endogenous agonist, anandamide [J].
Axelrod, J ;
Felder, CC .
NEUROCHEMICAL RESEARCH, 1998, 23 (05) :575-581
[4]
Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides [J].
Barg, J ;
Fride, E ;
Hanus, L ;
Levy, R ;
MatusLeibovitch, N ;
Heldman, E ;
Bayewitch, M ;
Mechoulam, R ;
Vogel, Z .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 287 (02) :145-152
[5]
Characterization of the hypnotic properties of oleamide [J].
Basile, AS ;
Hanus, L ;
Mendelson, WB .
NEUROREPORT, 1999, 10 (05) :947-951
[6]
Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells [J].
Bisogno, T ;
Sepe, N ;
Melck, D ;
Maurelli, S ;
DePetrocellis, L ;
DiMarzo, V .
BIOCHEMICAL JOURNAL, 1997, 322 :671-677
[7]
Secondary structure peptide mimetics:: Design, synthesis, and evaluation of β-strand mimetic thrombin inhibitors [J].
Boatman, PD ;
Ogbu, CO ;
Eguchi, M ;
Kim, HO ;
Nakanishi, H ;
Cao, BL ;
Shea, JP ;
Kahn, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (08) :1367-1375
[8]
Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide [J].
Boger, DL ;
Patterson, JE ;
Guan, XJ ;
Cravatt, BF ;
Lerner, RA ;
Gilula, NB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :4810-4815
[9]
Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid oleamide [J].
Boger, DL ;
Patterson, JE ;
Jin, Q .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (08) :4102-4107
[10]
Boger DL, 1998, CURR PHARM DESIGN, V4, P303